Related Experiment Video
Updated: Apr 15, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
BmKn-2 scorpion venom peptide for killing oral cancer cells by apoptosis
Pirut Tong-ngam1, Sittiruk Roytrakul, Hathaitip Sritanaudomchai
1Institute of Molecular Biosciences, Nakhon Pathom, Thailand
Abstract:
Scorpion venom peptides recently have attracted attention as alternative chemotherapeutic agents that may overcome the limitations of current drugs, providing specific cytotoxicity for cancer cells with an ability to bypass multidrug-resistance mechanisms, additive effects in combination therapy and safety. In the present study, BmKn-2 scorpion venom peptide and its derivatives were chosen for assessment of anticancer activities. BmKn-2 was identified as the most effective against human oral squamous cells carcinoma cell line (HSC-4) by screening assays with an IC50 value of 29 μg/ml. The BmKn-2 peptide killed HSC-4 cells through induction of apoptosis, as confirmed by phase contrast microscopy and RT-PCR techniques. Typical morphological features of apoptosis including cell shrinkage and rounding characteristics were observed in treated HSC-4 cells. The results were further confirmed by increased expression of pro-apoptotic genes such as caspase-3, -7, and -9 but decrease mRNA level of anti-apoptotic BCL-2 in BmKn-2 treated cells, as determined by RT-PCR assay. In summary, the BmKn-2 scorpion venom peptide demonstrates specific membrane binding, growth inhibition and apoptogenic activity against human oral cancer cells.
Insights
Scorpion venom peptide BmKn-2 shows potent anticancer activity against oral cancer cells by inducing apoptosis. This peptide offers a promising alternative to conventional chemotherapy, bypassing drug resistance mechanisms.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Scorpion venom peptides are emerging as novel chemotherapeutic agents.
- They offer specific cytotoxicity and can overcome multidrug resistance.
- Potential for combination therapy and improved safety profiles exist.
Purpose of the Study:
- To assess the anticancer activities of the BmKn-2 scorpion venom peptide and its derivatives.
- To evaluate the efficacy of BmKn-2 against human oral squamous cell carcinoma (HSC-4).
Main Methods:
- Screening assays to identify effective peptides.
- In vitro studies using the HSC-4 cell line.
- Phase contrast microscopy and Reverse Transcription Polymerase Chain Reaction (RT-PCR) to analyze apoptosis.
Main Results:
- BmKn-2 demonstrated significant cytotoxicity against HSC-4 cells with an IC50 of 29 μg/ml.
- Apoptosis induction in HSC-4 cells was confirmed by morphological changes and RT-PCR.
- Increased expression of pro-apoptotic genes (caspase-3, -7, -9) and decreased BCL-2 mRNA levels were observed.
Conclusions:
- BmKn-2 scorpion venom peptide exhibits specific membrane binding, growth inhibition, and apoptogenic activity against human oral cancer cells.
- BmKn-2 represents a potential therapeutic candidate for oral cancer treatment.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

